1 Comparison of 11C-methionine and 18F-FDG PET-CT for staging and follow-up of pediatric lymphoma Sue C. Kaste 1, 2, 3 , Scott E. Snyder 1 , Monika L. Metzger 2, 4, , John T. Sandlund 2, 4 , Scott C. Howard 5 , Matthew Krasin 6 , Barry L Shulkin 1, 3 1 Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN 2 Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 3 Department of Radiology, University of Tennessee, School of Health Sciences, Memphis, TN 4 Department of Pediatrics, University of Tennessee, School of Health Sciences, Memphis, TN 5 School of Health Studies, University of Memphis, Memphis, TN 6 Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN Corresponding Author and Reprint request: Sue C. Kaste, DO Department of Diagnostic Imaging 262 Danny Thomas Place, MSN #220 Memphis, TN 38105 Phone: 901-595-7561 Fax: 901-595-3981 e-mail: [email protected]Running title: 11C-MET or 18F-FDG PET-CT for lymphoma 39 characters with spaces WC=4390 total Supported in part by grant P30 CA-21765 from the National Institutes of Health, a Center of Excellence grant from the State of Tennessee, and the American Lebanese Syrian Associated Charities (ALSAC). Journal of Nuclear Medicine, published on September 8, 2016 as doi:10.2967/jnumed.116.178640 by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
21
Embed
Journal of Nuclear Medicine, published on September 8, 2016 as …jnm.snmjournals.org/content/early/2016/09/07/jnumed.116... · 2016-09-07 · 1 Comparison of 11C-methionine and 18F-FDG
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Comparison of 11C-methionine and 18F-FDG PET-CT for staging and follow-up of pediatric lymphoma
Sue C. Kaste1, 2, 3, Scott E. Snyder1, Monika L. Metzger2, 4, , John T. Sandlund 2, 4, Scott C. Howard5, Matthew Krasin6, Barry L Shulkin1, 3
1Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, Memphis, TN
2Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN 3Department of Radiology, University of Tennessee, School of Health Sciences, Memphis, TN 4Department of Pediatrics, University of Tennessee, School of Health Sciences, Memphis, TN 5School of Health Studies, University of Memphis, Memphis, TN 6 Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN
Corresponding Author and Reprint request: Sue C. Kaste, DO
Department of Diagnostic Imaging 262 Danny Thomas Place, MSN #220 Memphis, TN 38105 Phone: 901-595-7561 Fax: 901-595-3981 e-mail: [email protected]
Running title: 11C-MET or 18F-FDG PET-CT for lymphoma 39 characters with spaces
WC=4390 total
Supported in part by grant P30 CA-21765 from the National Institutes of Health, a Center of Excellence grant from
the State of Tennessee, and the American Lebanese Syrian Associated Charities (ALSAC).
Journal of Nuclear Medicine, published on September 8, 2016 as doi:10.2967/jnumed.116.178640by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
1. Miyazawa H, Arai T, Iio M, Hara T. PET imaging of non‐small‐cell lung carcinoma with carbon‐11‐methionine: relationship between radioactivity uptake and flow‐cytometric parameters. J Nucl Med. 1993;34:1886‐1891.
2. Harris SM, Davis JC, Snyder SE, et al. Evaluation of the biodistribution of 11C‐methionine in children and young adults. J Nucl Med. 2013;54:1902‐1908.
3. Beadsmoore C, Newman D, MacIver D, Pawaroo D. Positron Emission Tomography Computed Tomography: A Guide for the General Radiologist. Can Assoc Radiol J. 2015;66:332‐347.
4. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B‐cell non‐Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773‐2780.
5. Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved‐field radiotherapy in early‐stage Hodgkin lymphoma: mature results of the G4 trial. Ann Oncol. 2013;24:1044‐1048.
6. Edwards‐Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan‐Kettering Cancer Center experience. Ann Oncol. 2010;21:574‐581.
7. Mauz‐Korholz C, Hasenclever D, Dorffel W, et al. Procarbazine‐free OEPA‐COPDAC chemotherapy in boys and standard OPPA‐COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH‐HD‐2002 study. J Clin Oncol. 2010;28:3680‐3686.
8. von Tresckow B, Plutschow A, Fuchs M, et al. Dose‐intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30:907‐913.
9. Sutinen E, Jyrkkio S, Varpula M, et al. Nodal staging of lymphoma with whole‐body PET: comparison of. J Nucl Med. 2000;41:1980‐1988.
10. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048‐3058.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
11. Culverwell AD, Scarsbrook AF, Chowdhury FU. False‐positive uptake on 2‐[(1)(8)F]‐fluoro‐2‐deoxy‐D‐glucose (FDG) positron‐emission tomography/computed tomography (PET/CT) in oncological imaging. Clin Radiol. 2011;66:366‐382.
12. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F‐fluorodeoxyglucose positron emission tomography ((18)F‐FDG‐PET) and a comparison of (18)F‐FDG‐pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652‐659.
13. Leskinen‐Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon‐11‐methionine and fluorodeoxyglucose in non‐Hodgkin's lymphoma: a PET study. J Nucl Med. 1991;32:1211‐1218.
14. Rodriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non‐Hodgkin's lymphoma. J Nucl Med. 1995;36:1790‐1796.
15. Heiss WD. Clinical impact of amino acid PET in gliomas. J Nucl Med. 2014;55:1219‐1220.
16. Nuutinen J, Leskinen S, Lindholm P, et al. Use of carbon‐11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med. 1998;25:729‐735.
17. Yoshida H, Yoshikawa K, Imazeki K, et al. [Correlation analysis between patlak plot and DAR using 11C‐methionine PET]. Nihon Igaku Hoshasen Gakkai Zasshi. 1995;55:582‐586.
18. Ogawa T, Kanno I, Hatazawa J, et al. Methionine PET for follow‐up of radiation therapy of primary lymphoma of the brain. Radiographics. 1994;14:101‐110.
19. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15:254‐266.
20. Oda K, Hosoda N, Endo H, et al. L‐type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010;101:173‐179.
21. Okubo S, Zhen HN, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of L‐methyl‐11C‐methionine (MET) uptake with L‐type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99:217‐225.
22. Dunet V, Rossier C, Buck A, Stupp R, Prior JO. Performance of 18F‐fluoro‐ethyl‐tyrosine (18F‐FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis. J Nucl Med. 2012;53:207‐214.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
23. Wang R, Zhu H, Chen Y, et al. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT. Hematol Oncol. 2014;32:126‐132.
24. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3'‐deoxy‐3'‐fluorothymidine‐PET in NHL patients: whole‐body biodistribution and imaging of lymphoma manifestations‐‐a pilot study. Cancer Biother Radiopharm. 2004;19:436‐442.
25. Buck AK, Kratochwil C, Glatting G, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775‐1782.
26. Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG‐ and FLT‐PET. Leuk Lymphoma. 2007;48:746‐753.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Figure 2. 22 year old woman with mediastinal lymphadenopathy. Biopsy showed nodular sclerosing Hodgkin lymphoma.
A. MIP images (11C-MET left, 18F-FDG right) show intense though variable uptake of both tracers throughout the mediastinal masses. (Small focus of 11C-MET appearing over the right mid-chest lay within the tubing leading to the central line). Images are normalized to SUVmax 5.0 for 11C-MET and 8.0 for 18F-FDG.
B. Transverse images (left column PET, middle column attenuation correction CT, right column fusion) through the lower aspect of the mediastinal mass (11C-MET top, 18F- FDG bottom). Uptake of both tracers is slightly heterogeneous but the regional distribution is largely concordant. Images are normalized to SUVmax 5.0 for 11C-MET and 8.0 for 18F-FDG.
Figure A.
Figure B.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Figure 3. 17 year old girl with mixed cellularity Hodgkin lymphoma. MIP images (11C-MET left, 18F-FDG right) show intense uptake in left cervical and supraclavicular masses. Images are normalized to SUVmax 7.0 for 11C-MET and 5.0 for 18F-FDG.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Figure 4. 15 year old girl with widespread nodular sclerosing Hodgkin lymphoma.
3A. Transverse images (left column PET, middle column attenuation correction CT, right column fusion ) through the upper aspect of the liver (11C-MET top, 18F-FDG bottom). Intense uptake of 11C-MET renders hepatic metastases to appear as areas of low activity in comparison to normal liver. Hepatic metastases are quite discernible on 18F-FDG images. Images are normalized to SUVmax 15.0 for 11C-MET and 7.0 for 18F-FDG.
3B. Contrast enhanced CT scan through the same region shows many areas of low attenuation consistent with extensive liver involvement.
Figure A.
Figure B.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Figure 5. 16 year old boy with mixed cellularity Hodgkin lymphoma. 11C-MET images following 8 weeks of chemotherapy and at presentation.
A. Transverse images following 8 weeks of chemotherapy (top row) and at presentation (bottom row) (left column PET, middle column attenuation correction CT, right column fusion ). There has been resolution of the abnormal 11C-MET activity and considerable reduction in size in the left cervical sites.
B. MIP images following 8 weeks of chemotherapy (left) and at presentation (right) show that activity within the neck has become normal during treatment.
Figure A.
Figure B.
by on October 28, 2020. For personal use only. jnm.snmjournals.org Downloaded from
Doi: 10.2967/jnumed.116.178640Published online: September 8, 2016.J Nucl Med. ShulkinSue Creviston Kaste, Scott E Snyder, Monika L Metzger, John T Sandlund, Scott Howard, Matthew Krasin and Barry L pediatric lymphoma
F-FDG PET-CT for staging and follow-up of18C-methionine and 11Comparison of
http://jnm.snmjournals.org/content/early/2016/09/07/jnumed.116.178640This article and updated information are available at:
Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/misc/permission.xhtmlInformation about reproducing figures, tables, or other portions of this article can be found online at:
and the final, published version.proofreading, and author review. This process may lead to differences between the accepted version of the manuscript
ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting,JNMcopyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the
. They have not beenJNM ahead of print articles have been peer reviewed and accepted for publication in JNM
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)1850 Samuel Morse Drive, Reston, VA 20190.SNMMI | Society of Nuclear Medicine and Molecular Imaging
is published monthly.The Journal of Nuclear Medicine